About Us

Invisio delivers innovative medicines helping to transform peoples’ lives.

Creating and delivering practical solutions to problems brought about by the supply of straightforward treatments to patients. Invisio improves the therapy experience of patients, resulting in better overall outcomes. Transforming the delivery and optimizing therapy options, resulting in better value for money for payer authorities.

A dynamic and customer-focused team, Invisio brings a wealth of experience to drug profiling, development and, ultimately, delivery to the carers and patients.

Invisio develops partnerships with providers, working alongside healthcare provision organisations to ensure prices remain acceptable and realistic for all involved.

Russ Pendleton, BSc MBA MIoD MBPsS MRSM

Experienced launch and commercialisation specialist. Particular expertise in the CNS field having launched three psychiatric drugs and managed two others. Also worked on therapies for neurological indications including Epilepsy, Stroke/TBI, Parkinson’s and Alzheimer’s Disease.

Initiated, managed and grown several conferences in CNS creating world-leading medical education events, these include Global Addiction, The International Review of Psychosis and Bipolarity, The Global College of Neuroprotection and Neuroregeneration and Winter Workshop in Schizophrenia.

Past editor of two journals; Aspects of Affect and International Journal of Neuroprotection and Neuroregeneration.

Inventor and entrepreneur with granted patents, and two developmental products that have been successfully out-licensed.  Russ studied Medical Science and Psychology at Newcastle University and added an MBA from Nottingham University Business School.

Al Hanson, AB MBA

Mr. Hansen is founder of KESA Partners, Inc., a private investment firm exclusively focused on investing in small companies in the pharma/medical device sector.

Mr. Hansen has over 30 years experience as a private equity investor and as an investment banker. He has been Chairman and/or CEO of a number of companies in the pharma/medical device sector including Questcor Pharmaceuticals, Cedarburg Pharmaceuticals, Molecular Medicine BioServices, Bioject and Bioserv. He has also served as a director of a number of other portfolio companies. KESA has also recently started several companies in the pharma/device sector. Mr. Hansen was previously a Managing Director at Signet Healthcare Partners and a Senior Vice President at Darby Overseas Investments.

He served as Director of Corporate Finance at the U.S. Treasury in the administration of George H. W. Bush. Prior to this, he was an investment banker with E.F. Hutton and Dillon Read. Mr. Hansen also served as a U.S. Army Special Forces officer.

Mr. Hansen has an A.B. from Princeton University and an M.B.A. (with distinction) from the Wharton School, University of Pennsylvania.